Table 2.

Summary of past and current clinical trials targeting components of the TME

Intervention	Trial Status			Outcome	Reference
	Current Phase	Trial Identifier	Status	Median Survival
Erlotinib + Gemcitabine	III	NCT00026338	Completed	6.24 mo vs 5.91 mo	6
Oxaliplatin + Irinotecan + Leucovorin + 5-FU	II/III	NCT00112658	Completed	11.1 mo vs 6.8 mo	7
GDC-0449 + Gemcitabine	II	NCT01064622	Active
IPI-926 + Gemcitabine	I/II	NCT01130142	Stopped	N/A
nab-Paclitaxel + Gemcitabine	I/II	NCT00398086	Completed	12.2 mo	48
PEGPH20 + Gemcitabine	I/II	NCT01453153	Active
Marimastat + Gemcitabine	III	N/A	Completed	5.44 mo vs 5.39 mo	65
Cilengitide + Gemcitabine	II	N/A	Completed	6.7 mo vs 7.7 mo	66
BAY 12-9566	III	N/A	Completed	3.7 mo vs 6.6 mo	67
Bevacizumab + Gemcitabine	III	NCT00088894	Completed	5.8 mo vs 5.9 mo	68
Bevacizumab + Erlotinib + Gemcitabine	III	N/A	Completed	7.1 mo vs 6.0 mo	69
Bevacizumab + Docetaxel Radiotherapy + Capecitabine + Bevacizumab, Bevacizumab + Gemcitabine	II	N/A	Completed	4.1 mo vs 5.4 mo	70
	II	NCT00114179	Completed	11.9	71
Axitinib + Gemcitabine	III	NCT00471146	Completed	8.5 mo vs 8.3 mo	72
Sorafenib + Gemcitabine	II	N/A	Completed	4.0 mo	73
RO4929097	II	NCT01232829	Active
MK0752 + Gemcitabine	I/II	NCT01098344	Active
Irradiated Allogeneic GM-CSF-Secreting Tumour Vaccine	II	NCT00084383	Completed	24.8 mo	101
MUC1 peptide-loaded Dendritic Cell Vaccine	I/II	N/A	Completed	26 mo	102
Ipilimumab	II	NCT00112580	Completed	N/A	103
CP-870,893 + Gemcitabine	I	NCT00711191	Completed	7.4 mo	104
Mechanistic Studies
GDC-0449 + Gemcitabine	0	NCT01195415	Active
GDC-0449	II	NCT01096732	Active
Preoperative Pimonidazole	N/A	NCT01248637	Active